Fairvalue-Calculator Fairvalue-Calculator
EN DE

Damora Therapeutics, Inc (DMRA) Fair Value & Analysis

Healthcare · US · Market cap $1.3B

Price$22.94
Fair Value$11.72
Upside-48.9%
Quality95/100
Evidence: Low Range $8.79 – $14.64

Fair value as of: Jun 24, 2026

Analysis

Damora Therapeutics, Inc (DMRA) currently trades at $22.94, while our model-based Fair Value estimate is $11.72 — implying the stock looks roughly 48.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Damora Therapeutics, Inc (DMRA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $11.72 versus a price of $22.94 — about −49% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DMRA?
Our 21-model fair value for Damora Therapeutics, Inc is $11.72 (as of Jun 24, 2026), built from audited fundamentals. The current price is $22.94.
What is the quality score of DMRA?
Damora Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.